Figure 4.

Anti-miR-33a/b ASO treatment reduced abnormal RPE cytoskeletal organization in the RPE cell layer of NHPs fed a high-fat/cholesterol diet

RPE flatmounts prepared from NHPs that received subcutaneous injections of vehicle or anti-miR-33 ASO for 6 weeks were stained with phalloidin and examined for RPE cytoskeletal organization, and then RPE cell size was quantified and segmented in the area closer to the optic nerve head (ONH), center, and periphery. Arrows in the top panel indicate enlarged RPE cells (n ≤ 7). Scale bar: 100 μm. RPE cell size was quantified in field of view (FOV) and represented in the bar graphs. All error bars represent ±SEM. Statistical differences between vehicle- and anti-miR-33 ASO-injected NHPs were calculated by unpaired t test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.